Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hepatic Encephalopathy Clear all
Not yet recruiting Not applicable Interventional

Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy

NCT07553858
View directory record Official record
Conditions
Hepatic Encephalopathy, Liver Cirrhosis, Portal Shunt Systemic
Interventions
Endoscopic ultrasound-guided transgastric embolization of the spontaneous portosystemic shunts, Interventional Radiology for shunt embolization/retrograde tranvenous obliteration
Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 7, 2026, 6:53 PM EDT
Recruiting Not applicable Interventional

Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

NCT06425380
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Resistant Potato Starch
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 7, 2026, 6:53 PM EDT
Withdrawn No phase listed Observational

Effect of Music on Attention and Prospective Memory in Hepatic Encephalopathy

NCT01882855
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy

NCT00999167
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
HPN-100, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
28
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

NCT00287235
View directory record Official record
Conditions
Hepatic Encephalopathy, Liver Failure, Hepatitis, Chronic, Liver Cirrhosis
Interventions
MARS, Standard Medical Therapy
Device · Drug
Lead sponsor
Vantive Health LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
6
States / cities
Birmingham, Alabama • San Diego, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 7, 2026, 6:53 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

NCT05297448
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin SSD, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
90
States / cities
Homewood, Alabama • Chandler, Arizona • Sun City, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 7, 2026, 6:53 PM EDT
Withdrawn Phase 3 Interventional

A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure

NCT02086825
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Sep 7, 2026, 6:53 PM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement

NCT06052176
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Albumin Infusion
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 7, 2026, 6:53 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

NCT05071716
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin SSD, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
139
States / cities
Dothan, Alabama • Chandler, Arizona • Peoria, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 7, 2026, 6:53 PM EDT
Completed No phase listed Observational

TIPS Plus Transvenous Obliteration for Gastric Varices

NCT04044248
View directory record Official record
Conditions
Cirrhosis, Liver, Hypertension, Portal, Esophageal and Gastric Varices, Bleeding Gastric, Encephalopathy
Interventions
TIPS-obliteration
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
8 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 7, 2026, 6:53 PM EDT
Completed No phase listed Observational

Autoregulation Assessment During Liver Transplantation

NCT01425385
View directory record Official record
Conditions
Liver Failure, Liver Transplantation, Encephalopathy
Interventions
Near infrared spectroscopy monitoring, Autoregulation monitoring
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 7, 2026, 6:53 PM EDT
Not yet recruiting Phase 2 Interventional

Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)

NCT07528690
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Microbiota transplant therapy (MTT) capsules, Placebo capsule
Biological · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
West Haven, Connecticut • Dallas, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 7, 2026, 6:53 PM EDT
Completed No phase listed Observational

A Multi-Center Group to Study Acute Liver Failure in Children

NCT00986648
View directory record Official record
Conditions
Acute Liver Failure, Hepatic Encephalopathy
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 18 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
17
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.

NCT01283152
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Portosystemic Encephalopathy, PSE
Interventions
Polyethylene glycol 3350-electrolyte solution (GoLYTELY®), Lactulose
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

NCT03585257
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Covert Hepatic Encephalopathy
Interventions
25% IV albumin, Placebo
Biological · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

AST-120 Used to Treat Mild Hepatic Encephalopathy

NCT00867698
View directory record Official record
Conditions
Mild Hepatic Encephalopathy
Interventions
AST-120
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Not applicable Interventional

CAREGIVER: A Trial to Improve the Burden and Distress of Caring for Persons With Decompensated Cirrhosis

NCT04205396
View directory record Official record
Conditions
Caregivers
Interventions
Written emotional disclosure, Resilience training, No treatment
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Sep 7, 2026, 6:53 PM EDT
Withdrawn Not applicable Interventional

HepQuant to Predict Hepatic Encephalopathy After TIPS

NCT04664621
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
HepQuant
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

NCT03712280
View directory record Official record
Conditions
Hepatic Cirrhosis, Hepatic Encephalopathy (HE)
Interventions
MNK6106, Rifaximin
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Coronado, California • Rialto, California • St. Petersburg, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Not applicable Interventional

A Study of Controlled Lactulose Withdrawal

NCT00914056
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
lactulose
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy

NCT00558038
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
AST-120, lactulose
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Sep 7, 2026, 6:53 PM EDT
Withdrawn No phase listed Observational

The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis

NCT01777971
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Ascites, Fatigue
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Sep 7, 2026, 6:53 PM EDT
Recruiting Not applicable Interventional

Affect of Melatonin on Sleep and Cognition in Cirrhosis

NCT07046429
View directory record Official record
Conditions
Hepatic Encephalopathy, Covert Hepatic Encephalopathy, Cirrhosis, Sleep Disturbances and Insomnia
Interventions
Melatonin tablet 3 mg once daily, Thiamine
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Phase 2Phase 3 Interventional Results available

13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF

NCT02786836
View directory record Official record
Conditions
Acute Liver Failure
Interventions
13C-Methacetin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 7, 2026, 6:53 PM EDT